IDH-mutant glioma
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
Phase 1 included.
Clear filters15 of 15 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
alkylating chemotherapy 2
No dated milestone in 2025 to 2030
No dated milestone in 2025 to 2030
ATR inhibitor (ATRX-altered) 1
TuvusertibPhase 2
No dated milestone in 2025 to 2030
DNMT inhibitor 1
No dated milestone in 2025 to 2030
mutant IDH1 inhibitor 3
FDA Fast Track granted, Aug 20, 2026
OlutasidenibPhase 2
No dated milestone in 2025 to 2030
IvosidenibPhase 1
No dated milestone in 2025 to 2030
mutant IDH1/IDH2 inhibitor 2
VorasidenibApproved
No dated milestone in 2025 to 2030
HMPL-306 (ranosidenib)Phase 3
No dated milestone in 2025 to 2030
PARP inhibitor 3
OlaparibPhase 2
No dated milestone in 2025 to 2030
Pamiparib + TemozolomidePhase 1
No dated milestone in 2025 to 2030
NiraparibPhase 1
No dated milestone in 2025 to 2030
PD-1 antibody 1
NivolumabPhase 2
No dated milestone in 2025 to 2030
peptide vaccine 1
No dated milestone in 2025 to 2030
retinoid plus PD-1 antibody 1
No dated milestone in 2025 to 2030